IRLAB Therapeutics (IRLAB) Q3 2026 earnings summary

Executive summary

• Strategic focus shifted from expanding the pipeline to business development, partnerships and monetizing existing assets; workforce reductions and a lower cost base are planned.

• Q3 net sales were SEK 6.9m and operating loss SEK 12.9m; 9M net sales rose to SEK 52.7m while operating loss narrowed to SEK 18.9m.

• A SEK 76.5m gross rights issue and overallotment strengthened liquidity, but the auditor highlighted material uncertainty about continuing as a going concern without further liquidity injections.

Financial highlights

• 9M total revenue was SEK 57.1m, including SEK 52.7m net sales: an Otsuka milestone of USD 3m (SEK 27.1m) and SEK 25.6m in service revenue.

• Q3 net sales were SEK 6.9m vs SEK 18.8m YoY; 9M net sales were SEK 52.7m vs SEK 42.7m.

• 9M operating loss was SEK 18.9m vs SEK 71.5m; net loss was SEK 23.3m vs SEK 86.5m; EPS was -SEK 0.22 vs -SEK 1.42.

• 9M operating expenses fell to SEK 76.0m from SEK 119.8m, largely reflecting lower clinical activity and cost-saving measures; R&D costs were SEK 60.4m.

• Cash and cash equivalents were SEK 90.6m at period-end vs SEK 110.1m a year earlier; 9M operating cash outflow was SEK 53.1m.

Outlook and guidance

• Resources are being redirected toward business development, strategic partnerships and value creation from existing programs; further cost-saving measures and workforce reductions are planned.

• Licensing and partnership discussions continue, but agreements are taking longer than anticipated and the likelihood of new partnership agreements in 2026 was reduced.

• Linepemat LIFT-PD results are expected in mid-2027; IRL1117 preclinical safety and toxicology work and manufacturing scale-up are intended to support a future Phase I application.

• Mesdopetam Phase III development requires funding through strategic partnerships or licensing; pirepemat work is focused on dose optimization and preparations for a future study.

• IRL942 development pace was reduced; required preclinical regulatory safety and toxicology studies are not expected to be completed before 2027.